Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.

Zhang X, Shu XO, Cai Q, Ruan Z, Gao YT, Zheng W
Clin Cancer Res. 2006 12 (20 Pt 1): 6037-42

PMID: 17062678 · DOI:10.1158/1078-0432.CCR-05-2851

PURPOSE - Plasminogen activator inhibitor-1 (PAI-1) plays an important role in cancer invasion and metastasis. A common polymorphism (4G/5G) in the promoter region of the PAI-1 gene has been reported to influence transcription and plasma levels of PAI-1. We evaluated the association between PAI-1 4G/5G polymorphism and breast cancer survival in a population-based cohort of breast cancer patients.

EXPERIMENTAL DESIGN - Included in this analysis were 1,083 Chinese women diagnosed with stage 0 to III primary breast cancer at age 25 to 64 years who were recruited between 1996 and 1998 for the Shanghai Breast Cancer Study and followed for a median of 5.2 years. The Kaplan-Meier method and Cox model were used to evaluate the genotype and survival association.

RESULTS - After adjustment for known prognostic factors for breast cancer, patients homozygous for the 4G allele had significantly poorer disease-free survival [hazard ratio (HR), 1.7; 95% confidence interval (95% CI), 1.1-2.4] and overall survival (HR, 1.5; 95% CI, 1.0-2.3) than those homozygous for the 5G allele. The association was more evident in patients with advanced disease. The HRs (95% CI) were 3.5 (1.4-9.0) for disease-free survival and 3.1 (1.1-8.3) for overall survival in stage III patients.

CONCLUSIONS - The PAI-1 4G/5G polymorphism may be a prognostic marker for young and middle-aged Chinese breast cancer patients.

MeSH Terms (12)

Breast Neoplasms China Female Genetic Markers Genetic Variation Humans Neoplasm Invasiveness Neoplasm Metastasis Plasminogen Activator Inhibitor 1 Prognosis Registries Survival Analysis

Connections (2)

This publication is referenced by other Labnodes entities: